How To Get A ‘Great Britain’ Drug Approval In 2021
Executive Summary
So much will change on the regulatory front next year that the UK drug regulator, the MHRA, has had to issue dozens of new guidance documents to help pharma and biotech firms navigate the new requirements and assessment routes. A key consideration is how the UK will handle centralized EU applications that are still pending on 31 December.
You may also be interested in...
Global Pharma Guidance Tracker – July 2020
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit
The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit.
Coronavirus Notebook: UK To Run Vaccine Challenge Studies, CEPI Expands Manufacturing Network
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: